Virchows Archiv reports on a 27-year-old man with stage IV duodenal neuroendocrine carcinoma who achieved a complete response to pembrolizumab after comprehensive genomic profiling revealed MSI-H and TMB-high status.
bit.ly/48A1ucY
bit.ly/48A1ucY